Skip Navigation


Carcinogenesis Advance Access originally published online on June 23, 2005
Carcinogenesis 2005 26(11):1975-1977; doi:10.1093/carcin/bgi164
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
26/11/1975    most recent
bgi164v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Frank, B.
Right arrow Articles by Burwinkel, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frank, B.
Right arrow Articles by Burwinkel, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis vol.26 no.11 © Oxford University Press 2005; all rights reserved.

Association of death receptor 4 haplotype 626C–683C with an increased breast cancer risk

Bernd Frank 1, *, Kari Hemminki 1, 2, Kalai S. Shanmugam 1, Alfons Meindl 3, Rüdiger Klaes 4, Rita K. Schmutzler 5, Barbara Wappenschmidt 5, Michael Untch 6, Peter Bugert 7, Claus R. Bartram 4 and Barbara Burwinkel 1

1 Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany, 2 Department of Biosciences at Novum, Karolinska Institute, Huddinge, Sweden, 3 Department of Gynaecology and Obstetrics, Klinikum rechts der Isar at the Technical University, Munich, Germany, 4 Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany, 5 Department of Gynaecology and Obstetrics, Division of Molecular Gynaeco-Oncology, Clinical Center University of Cologne, Germany, 6 Department of Gynaecology and Obstetrics at the Ludwig-Maximilians-University, Munich, Germany and 7 Institute of Transfusion Medicine and Immunology, Red Cross Blood Service of Baden-Württemberg-Hessia, Faculty of Clinical Medicine, University of Heidelberg, Mannheim, Germany

* To whom correspondence should be addressed. Tel: +49 6221 421802; Fax: +49 6221 421810; Email: b.frank{at}dkfz.de

Dysregulation of apoptosis plays a crucial role in carcinogenesis. Tumour necrosis factor-related apoptosis-inducing ligand stimulates the extrinsic apoptotic pathway by binding to death receptor 4 (DR4). Thus, genetic alterations within the candidate tumour suppressor gene DR4 would be expected to provoke a deficient apoptotic signalling thereby facilitating the development of cancer. The DR4 variants Thr209Arg and Glu228Ala were genotyped in a series of 521 breast cancer cases and 1100 control subjects from Germany, determining their impact on breast cancer risk. Neither Thr209Arg (626C>G) nor Glu228Ala (683A>C) alone were significantly associated with breast cancer risk [odds ratio (OR) = 0.84, 95% confidence interval (CI) = 0.65–1.08, P = 0.18 and OR = 0.89, 95% CI = 0.72–1.12, P = 0.30]. However, haplotype analysis revealed a 3.5-fold risk for carriers of the 626C–683C haplotype (OR = 3.52, 95% CI = 1.45–8.52, P = 0.003).


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
B. Frank, K. S. Shanmugam, L. Beckmann, K. Hemminki, H. Brenner, M. Hoffmeister, J. Chang-Claude, and B. Burwinkel
Death receptor 4 variants and colorectal cancer risk.
Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 2002 - 2005.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.